{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-23-000159","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.354873+00:00","generated_at":"2026-06-07T09:56:46.351245+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunovant reports positive initial Phase 2 data for batoclimab in Graves' disease; IgG reduction up to 87%","bullets":["Initial cohort in Phase 2 trial exceeded 50% response rate; response defined as normalization of T3/T4 without increasing ATD dose.","680 mg SC batoclimab showed IgG reduction up to 87% (mean 81%) after 12 weeks; 340 mg produced lower IgG reductions.","Dose response observed on anti-TSHR autoantibodies and clinical parameters including ATD dose reduction/discontinuation.","Batoclimab generally well tolerated with no new safety signals.","CEO says intent to focus future Graves' development on IMVT-1402, with plans announced later in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-23-000159","json":"https://secwatch.observer/filing/0001764013-23-000159.json","markdown":"https://secwatch.observer/filing/0001764013-23-000159.md","text":"https://secwatch.observer/filing/0001764013-23-000159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000159/0001764013-23-000159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000159/imvt-20231220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:56:46.351245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}